Engflag

CTP

Quick links to important sections

CTP

There is no image.

Method of action: Antidepressant, Blocking The Reuptake Of Serotonin, Psychoanaleptics

Treatment option: Agoraphobia, Generalized Anxiety Disorder, Depression, Obsessive Compulsive Disorder, Obsessive Compulsive Personality Disorder, Panic, Anxiety&Panic Attacks, Panic Attacks And Panic Disorder, Phobia, Phobia,Social

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of CTP

Property Description
Active ingredient Escitalopram
Form Oral Tablet (e.g., film-coated)
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
General purpose Mood stabilization and anxiety relief
Origin Synthetic compound

What Type of Medicine is CTP (Escitalopram)?

CTP is a synthetic, prescription-only antidepressant and psychotropic agent containing the single active ingredient, Escitalopram. It is scientifically classified within the Selective Serotonin Reuptake Inhibitor (SSRI) pharmacological class. Escitalopram is the International Nonproprietary Name (INN) for the drug, with CTP serving as one of its recognized trade names, alongside others such as Cipralex and Lexapro.

CTP is designed to target specific chemical pathways in the brain to help regulate mood and emotional stability. The active ingredient, Escitalopram, is chemically defined as the purified S-enantiomer of the related compound, citalopram. This specific molecular configuration is clinically recognized for delivering a highly focused therapeutic effect. Escitalopram is recognized as a core treatment for major depressive episodes.

Composition, Form, and General Purpose of CTP

CTP is a single-ingredient product manufactured as a stable oral dosage form, typically presented as a film-coated tablet intended for ingestion. The tablets are composed of the active substance, Escitalopram (often utilized as the oxalate salt for stability), combined with necessary pharmaceutical excipients. This single-entity formulation ensures predictable action.

The medicine's purpose is linked directly to its classification as an SSRI. Its general function is to support the brain's ability to maintain a balanced emotional state by gently and selectively increasing the availability of the neurotransmitter serotonin in the pathways between nerve cells. By optimizing this chemical environment, CTP aims to stabilize mood, alleviate pervasive feelings of low mood or despair, and reduce symptoms of excessive worry.

What side effects are possible with CTP?

Possible Side Effects and Safety Information

The safety profile of CTP (Escitalopram) is formally documented in government regulatory documents, classifying adverse reactions by frequency and the physiological system affected.

Commonly Classified Adverse Reactions

Adverse events are categorized according to regulatory standards (e.g., EMA/FDA). The most frequently reported adverse reactions, classified as Very Common (occurring in 1 in 10 patients or more), include headache and nausea. Reactions classified as Common (1 in 100 to less than 1 in 10 patients) include insomnia or somnolence, fatigue, increased sweating, dry mouth, dizziness, and sexual dysfunction (such as decreased libido and ejaculation disorders).

System-Organ Classes and Serious Adverse Events

Side effects are grouped by their impact on System-Organ Classes, such as Gastrointestinal Disorders (diarrhea, constipation) and Nervous System Disorders. The official label details specific, potentially serious adverse reactions. The most critical safety information includes a formal Boxed Warning concerning the increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults, particularly during treatment initiation or dose adjustment.

Other serious documented risks include the potential for Serotonin Syndrome (a severe serotonergic state), QT interval prolongation (a heart rhythm disturbance), and clinically significant abnormal bleeding events. Safety-related restrictions include a contraindication for individuals with pre-existing congenital long QT syndrome or those concurrently receiving MAO inhibitors.

Population-Specific Safety Notes

The regulatory profile outlines specific considerations for certain patient populations. For instance, older adults may be at an increased risk of hyponatraemia (low sodium levels) and bleeding. Furthermore, a lower maximum dose is often specified for individuals with hepatic impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory labeling documents the specific manifestations and required emergency actions for Escitalopram (CTP) overdosage. Immediate medical attention must be sought for any suspected overdose due to the risk of severe, life-threatening outcomes. The official documentation states that no specific antidote is known for this medication.

Documented Overdose Manifestations

Official labeling describes overdose presentations that typically include Somnolence (drowsiness), Dizziness, Tremor, and gastrointestinal distress such as Nausea or Vomiting. More severe presentations involve Convulsions (seizures) and Coma. Overdose can lead to critical cardiovascular toxicity, including Prolonged QT interval on the ECG and Ventricular Arrhythmias, such as Torsade de pointes.

Regulator-Mandated Emergency Management

Treatment for overdosage is symptomatic and supportive. The required clinical response involves ensuring a clear airway and continuous monitoring of vital signs and cardiac rhythm (ECG). The administration of Activated Charcoal or Gastric Lavage may be considered by medical professionals to reduce absorption. If the potentially fatal Serotonin Syndrome is suspected, the regulatory mandate is to discontinue the medicine and initiate specific supportive treatment.

Therapeutic Uses of CTP

What CTP Treats: Main Uses and Benefits

CTP (Escitalopram) is applied in therapeutic contexts involving certain distressing symptoms where heightened mood and anxiety manifestations interfere significantly with daily life. It is commonly used when supportive symptom management is appropriate, provides support that helps ease the overall symptom burden and may assist with maintaining functional stability. The medication is relevant across major symptom domains that disrupt emotional and functional stability.

The medication is applied in addressing conditions involving episodic or fluctuating manifestations, such as Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), and Panic Disorder, as well as being applied in addressing symptom clusters related to Social Anxiety Disorder, Obsessive-Compulsive Disorder (OCD), and Premenstrual Dysphoric Disorder (PMDD). It may assist in addressing these symptom clusters, offering symptomatic relief that **helps patients cope more steadily with symptom fluctuations.

“The medication is applied in scenarios where additional management of discomfort is required to support general well-being.”

Quick Fact: Supportive Relief for Persistent Low Mood and Excessive Worry

CTP is relevant in contexts involving heightened systemic burden, such as enduring sadness, guilt, anhedonia (loss of pleasure), and chronic, uncontrollable apprehension. It contributes to improved comfort during these periods of heightened symptoms.

Eligibility and Restrictions for Use

Who Can and Cannot Use CTP?

This section outlines the official population eligibility and non-eligibility rules for CTP (Escitalopram), strictly as stated in governmental regulatory documents.

Category Eligibility Rule (Official Labeling)
Absolute Contraindications Use is prohibited in patients with known hypersensitivity to Escitalopram or Citalopram, or those concurrently receiving MAOIs, Pimozide, Linezolid, Intravenous Methylene Blue, or medicinal products known to prolong the QT interval or with a history of congenital long QT syndrome.
Age Group Eligibility Use is established for adults (18 years and older). Use is established for adolescents (12–17) for Major Depressive Disorder (MDD). Use in pediatric patients under 12 for MDD is not established. EMA/non-US labels typically do not recommend use in patients under 18 years.
Conditional Use Use requires special consideration and caution in elderly patients (ge 65), patients with hepatic impairment, or those with severe renal impairment due to altered drug clearance. Caution is also necessary for patients with a history of mania/hypomania or unstable epilepsy.
Pregnancy/Lactation Pregnancy use is permitted only if the potential benefit justifies the potential risk to the fetus. For lactation, caution should be exercised, and some international documents do not recommend use during breastfeeding.

These regulatory classifications define who is permitted to use CTP, who is explicitly prohibited, and who requires restricted use due to specific age or health status.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Escitalopram (CTP) is structured around mandatory prohibitions and the documented potential for pharmacokinetic and pharmacodynamic interactions as defined in regulatory labeling.

Classification Interacting Agent or Category Constraint or Outcome
Contraindicated Combinations Monoamine Oxidase Inhibitors (MAOIs), including Pimozide and Linezolid Co-administration is prohibited due to the risk of Serotonin Syndrome or increased exposure leading to cardiotoxicity.
Mandatory Timing Rule MAOIs A 14-day washout period is required when switching between CTP and any psychiatric MAOI.
Pharmacokinetic Effects CYP2D6 Substrates CTP is a weak inhibitor of the CYP2D6 enzyme, resulting in a documented increase in the plasma concentration of co-administered substrates like Desipramine.
Exposure Modification CYP2C19 Inhibitors (e.g., Omeprazole) Co-administration increases Escitalopram's own systemic plasma concentration.
Pharmacodynamic Risks Serotonergic Agents (e.g., Triptans), St. John's Wort Documented potential for an additive effect, increasing the risk of Serotonin Syndrome.
Hemostasis Effects NSAIDs, Warfarin Combination use is associated with an increased regulatory risk of abnormal bleeding.

The official labels establish clear restrictions, with specific agents requiring absolute prohibition or monitored co-administration. Individuals identified as CYP2C19 poor metabolizers are noted to have a higher systemic exposure to CTP. CTP can be taken without regard to food, and co-use with alcohol is generally advised against due to potential additive central nervous system effects.

Mechanism of Action

Selective Serotonin Availability Enhancement

The primary mechanism of CTP (Escitalopram) involves selective inhibition of the Serotonin Transporter ( SERT), the protein that clears serotonin ( 5-HT) from the space between nerve cells. By blocking this reabsorption, the drug causes an acute and localized increase in 5-HT concentration. The action is restricted to the central serotonergic system and exhibits low affinity for other major monoamine transporters and receptors.

Adaptive Neural Circuit Rebalancing and Delayed Effect

This initial molecular step forces a time-dependent adaptation in the affected neural circuits. Specifically, the acute 5-HT elevation triggers the eventual desensitization and downregulation of inhibitory 5-HT1 A autoreceptors, a process that takes several weeks. This adaptive rebalancing removes the functional "brake" on 5-HT release and contributes to sustained modulation of serotonergic flow to key neural circuits associated with emotional processing.

Dosage and Administration Information

How to Use CTP

The administration of CTP (Escitalopram) follows standardized protocols that govern the route, frequency, and dose limits, as outlined in prescribing information. The medication is formulated as an oral dosage form, available as film-coated tablets (e.g., 10 mg and 20 mg strengths) and an oral solution (1 mg/mL).

Official Administration Guidelines

CTP is always taken orally and administered as a single dose once daily, which may be taken in the morning or evening. The intake is not dependent on mealtimes, meaning it can be administered with or without food.

Instruction Detail
Standard Adult Dose The initial and most common recommended dose is 10 mg once daily.
Maximum Daily Dose Dosing generally should not exceed 20 mg once daily for adults.
Dose Titration Dose adjustments are typically implemented after a minimum of one week of treatment.
Tablet Handling The scored 10 mg and 20 mg tablets may be divided to achieve specific dosing.

Procedural and Population Constraints

The usage protocol includes specific limitations for certain patient groups. For older adults (65 years) and those with documented hepatic (liver) impairment, the maximum recommended dose is typically restricted to 10 mg once daily. Additionally, for the oral solution, the use of a calibrated measuring device is instructed to ensure accurate dose volume.

Discontinuation of CTP must follow a specific process. Treatment should not be stopped abruptly; instead, a gradual dose reduction (tapering) should be implemented to align with proper procedural use guidelines.

Recent Clinical Evidence

Research evidence / Overview of Studies for CTP

Evidence for Use in Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)

This section will summarize the structure of the clinical evaluation for MDD and GAD, focusing on the types of short-term randomized trials and long-term maintenance studies that defined the primary outcomes measured in these conditions.

Research exploring the use of CTP in individuals with Major Depressive Disorder (MDD) has primarily relied on numerous short-term, randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time and involved comparisons with an inactive substance (placebo). Outcomes monitored included validated scales, such as the MADRS and HAM-D, which are relevant in evidence describing how symptom intensity is measured. These findings describe patterns observed in the studies related to symptom response and monitored the proportion of participants who showed minimal scores on the scales.

For individuals with Generalized Anxiety Disorder (GAD), studies similarly consisted of short-term RCTs that measured symptom outcomes. Researchers monitored scores on the HAM-A and Global Clinical Status scales. Studies report how symptoms evolved in the observed populations during the initial treatment phases, typically lasting 8 to 12 weeks.

Research Structure for Anxiety and Related Disorders

This subsection will outline the specific study designs, key outcomes examined, and populations included in clinical research for conditions such as Panic Disorder, Social Anxiety Disorder, and Obsessive-Compulsive Disorder.

Research examined panic attack frequency and outcomes related to daily functioning for Panic Disorder (PD). Studies focusing on Social Anxiety Disorder (SAD) and Obsessive-Compulsive Disorder (OCD) explored changes in symptom severity using specialized clinical scales. The volume of dedicated clinical research for these conditions remains limited compared to that for MDD or GAD, but studies contribute to the broader evidence landscape, detailing patterns of change in specific symptom clusters.

How should CTP be stored and disposed of?

How to Store and Dispose of CTP: Official Regulatory Requirements

Official labeling mandates specific conditions to maintain CTP's quality and integrity. All storage and disposal instructions are derived from authoritative government regulatory documents.

Mandatory Storage Conditions

Requirement Official Regulatory Statement
Temperature Control Store at a specific temperature, such as below 25 C or refrigerated (2 C - 8 C). Do not freeze.
Environmental Protection Keep the product in its original container, protected from light and moisture.
Stability Use the prepared solution within the specified in-use period (e.g., X hours); discard unused portions.

Disposal and Safety

Disposal Mandate: Do not dispose of CTP via household waste or by flushing it down the drain. Unused or expired medication must be handled according to local requirements for pharmaceutical or specialized hazardous waste collection.

Child Safety: CTP must always be stored securely out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagCanada

Equivalent of CTP found in:

A-Z Index: